Novel therapeutics from breakthrough research
in gastrointestinal disorders and diseases
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYPD) is a public, development-stage biopharmaceutical company that develops drugs to treat gastrointestinal (GI) conditions and diseases.
Our patented drug candidates, currently in clinical development, were discovered and developed in-house by Synergy scientists.
The company has its headquarters in New York City and also operates a research laboratory in Doylestown, PA that supports Synergy’s drug development programs.
Synergy’s drug development program and patent estate are based on a class of synthetic peptides designed to mimic uroguanylin, a human hormone that regulates intestinal fluid transport.
Synergy has a lead drug, Plecanatide, in clinical development to treat chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). A second drug, SP-333, is in pre-clinical development for GI diseases.
Lead Drug Development Program: Plecanatide
The market opportunity for gastrointestinal therapeutics was recently valued at around $50 BN in 2008. The US market which comprises almost 40% of the estimated global market is worth almost $19 BN.
Chronic constipation and IBS-C have a wide prevalence, affecting up to 15% and 20% of the population respectively. More than 100 million people worldwide suffer from these conditions.
Gastrointestinal Disorders (GI) & Diseases
Home >> Welcome
Synergy News Highlights
8 Feb 2012 Synergy Pharmaceuticals Engages The Trout Group for Investor Relations Services
4 Jan 2012 European Patent Office Upholds Synergy Pharmaceuticals’ Grant of Claims to Plecanatide
13 Dec 2011 Synergy Pharmaceuticals Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
13 Dec 2011 Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6 Dec 2011 Synergy Pharmaceuticals Announces Closing of Public Offering of 1,875,000 Units
